With Gilead and AbbVie posting essentially perfect phase 2 data with their hepatitis-C treatments, the bar has been set very high for those looking to join the race. To that end, Achillion shares are under pressure today after releasing interim data for one of its NS5A inhibitors targeting the disease. As Brenton Flynn discusses in the following video, this severe reaction to such a small data set reflects the paradigm shift in investor expectations around hepatitis-C treatments.
